BG105559A - Стабилен фармацевтичен състав включващ hmg - coa редуктазен инхибитор - Google Patents
Стабилен фармацевтичен състав включващ hmg - coa редуктазен инхибиторInfo
- Publication number
- BG105559A BG105559A BG105559A BG10555901A BG105559A BG 105559 A BG105559 A BG 105559A BG 105559 A BG105559 A BG 105559A BG 10555901 A BG10555901 A BG 10555901A BG 105559 A BG105559 A BG 105559A
- Authority
- BG
- Bulgaria
- Prior art keywords
- hmg
- coa reductase
- pharmaceutical formulation
- reductase inhibitor
- stable pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Изобретението се отнася до стабилен твърд фармацевтичен състав за лечение на хиперхолестеринемия и хиперлипидемия. Съставът включва като активен компонент HMG-CоА редуктазен инхибитор, като аторвастатин, правастатин, флувастатин и церивастатин или техни фармацевтично приемливи соли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9800309A SI20109A (sl) | 1998-12-16 | 1998-12-16 | Stabilna farmacevtska formulacija |
PCT/IB1999/001749 WO2000035425A1 (en) | 1998-12-16 | 1999-10-29 | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105559A true BG105559A (bg) | 2001-12-29 |
Family
ID=20432372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105559A BG105559A (bg) | 1998-12-16 | 2001-06-04 | Стабилен фармацевтичен състав включващ hmg - coa редуктазен инхибитор |
Country Status (25)
Country | Link |
---|---|
US (3) | US6680341B1 (bg) |
EP (2) | EP1911445A3 (bg) |
JP (1) | JP2002532409A (bg) |
KR (1) | KR100638307B1 (bg) |
CN (1) | CN1198597C (bg) |
AT (1) | ATE380020T1 (bg) |
AU (1) | AU775946B2 (bg) |
BG (1) | BG105559A (bg) |
CA (1) | CA2348988C (bg) |
CZ (1) | CZ302562B6 (bg) |
DE (1) | DE69937691T2 (bg) |
ES (1) | ES2299265T3 (bg) |
HR (1) | HRP20010325A2 (bg) |
HU (1) | HUP0104258A3 (bg) |
IL (2) | IL143759A0 (bg) |
IS (1) | IS5939A (bg) |
NZ (1) | NZ511260A (bg) |
PL (1) | PL347686A1 (bg) |
RU (1) | RU2227019C2 (bg) |
SI (2) | SI20109A (bg) |
SK (1) | SK8092001A3 (bg) |
TR (1) | TR200101235T2 (bg) |
WO (1) | WO2000035425A1 (bg) |
YU (1) | YU35501A (bg) |
ZA (1) | ZA200103802B (bg) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679534B2 (en) * | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
AU5328701A (en) | 2000-04-10 | 2001-10-23 | Teva Pharma | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
ATE260101T1 (de) | 2000-06-09 | 2004-03-15 | Lek Tovarna Farmacevtskih | Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
CZ20024015A3 (cs) † | 2000-06-09 | 2003-04-16 | Lek Pharmaceutical D.D. | Stabilní farmaceutický produkt a jeho formulace |
US20050215636A1 (en) * | 2000-10-05 | 2005-09-29 | Vilmos Keri | Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
PL369268A1 (en) * | 2001-03-27 | 2005-04-18 | Ranbaxy Laboratories Limited | A stable pharmaceutical composition of pravastatin |
GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
WO2003000177A2 (en) * | 2001-06-21 | 2003-01-03 | Andrx Pharmaceuticals, Inc. | Stable controlled release pharmaceutical compositions containing pravastatin |
JP2003055217A (ja) * | 2001-08-10 | 2003-02-26 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
EP1905431A1 (en) * | 2002-01-11 | 2008-04-02 | Circ Pharma Research and Development Limited | Pravastatin pharmaceutical formulations and methods of their use |
WO2003057195A1 (en) * | 2002-01-11 | 2003-07-17 | Athpharma Limited | Pravastatin pharmaceutical formulations and methods of their use |
KR20040101229A (ko) * | 2002-02-14 | 2004-12-02 | 랜박시 래보러터리스 리미티드 | 알칼리 금속 첨가에 의해 안정화된 아토르바스타틴 배합물 |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
SE0202365D0 (sv) * | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
EP1551356A2 (en) * | 2002-09-03 | 2005-07-13 | Biovail Laboratories Incorporated | Pravastatin pharmaceutical formulations and methods of their use |
CA2509688A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
EP1737449A1 (en) * | 2004-03-01 | 2007-01-03 | LEK Pharmaceuticals D.D. | Pharmaceutical composition |
KR100598326B1 (ko) | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
WO2006008757A2 (en) * | 2004-05-05 | 2006-01-26 | Cadila Healthcare Limited | Stabilized pharmaceutical compositions of pravastatin |
BRPI0514189A (pt) * | 2004-08-06 | 2008-06-03 | Transform Pharmaceuticals Inc | composições farmacêuticas de estatina e métodos de tratamento relacionados |
US20090149533A1 (en) * | 2004-08-06 | 2009-06-11 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
US20090208539A1 (en) | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
CA2615941A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
US20090247603A1 (en) | 2005-12-23 | 2009-10-01 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
WO2008062476A2 (en) * | 2006-10-31 | 2008-05-29 | Glenmark Pharmaceutical Limited | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof |
BG934U1 (bg) * | 2006-12-14 | 2007-11-30 | "Софарма" Ад | Състав за твърда лекарствена форма, съдържащ правастатин |
WO2009000286A1 (en) * | 2007-06-25 | 2008-12-31 | Parmatheen S.A. | Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
GB0713707D0 (en) * | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
WO2011049122A1 (ja) * | 2009-10-21 | 2011-04-28 | 第一三共株式会社 | プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法 |
US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
TR201005326A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Çoklu dozaj formları. |
WO2012002464A1 (ja) * | 2010-06-30 | 2012-01-05 | 持田製薬株式会社 | ω3脂肪酸の配合製剤 |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
WO2012141160A1 (ja) * | 2011-04-12 | 2012-10-18 | 沢井製薬株式会社 | ピタバスタチン含有製剤及びその製造方法 |
WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
RU2014124118A (ru) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | Фармацевтические препараты, включающие аторвастатин и глимепирид |
KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US579837A (en) * | 1897-03-30 | Saw-sharpening machine | ||
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
JP3254219B2 (ja) | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のci−981製剤およびその製法 |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
DE122011000014I1 (de) * | 1995-12-22 | 2011-11-03 | Kowa Co | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium. |
FR2751316B1 (fr) * | 1996-07-19 | 1998-08-28 | Granger Maurice | Appareil distributeur de bandes de papier ouate pour essuie-mains, papier toilette et similaire |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
ATE260101T1 (de) * | 2000-06-09 | 2004-03-15 | Lek Tovarna Farmacevtskih | Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung |
SI21302A (sl) * | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
TW589178B (en) * | 2003-02-21 | 2004-06-01 | China Chemical & Pharmaceutica | A novel industrial process to obtain pravastatin sodium of high purity |
-
1998
- 1998-12-16 SI SI9800309A patent/SI20109A/sl not_active IP Right Cessation
-
1999
- 1999-10-29 RU RU2001115716/15A patent/RU2227019C2/ru not_active IP Right Cessation
- 1999-10-29 AU AU63608/99A patent/AU775946B2/en not_active Ceased
- 1999-10-29 NZ NZ511260A patent/NZ511260A/xx unknown
- 1999-10-29 KR KR1020017006808A patent/KR100638307B1/ko not_active IP Right Cessation
- 1999-10-29 WO PCT/IB1999/001749 patent/WO2000035425A1/en active IP Right Grant
- 1999-10-29 CN CNB998144037A patent/CN1198597C/zh not_active Expired - Fee Related
- 1999-10-29 ES ES99951034T patent/ES2299265T3/es not_active Expired - Lifetime
- 1999-10-29 CA CA002348988A patent/CA2348988C/en not_active Expired - Fee Related
- 1999-10-29 DE DE69937691T patent/DE69937691T2/de not_active Expired - Lifetime
- 1999-10-29 SI SI9931000T patent/SI1148872T1/sl unknown
- 1999-10-29 EP EP07122298A patent/EP1911445A3/en not_active Withdrawn
- 1999-10-29 HU HU0104258A patent/HUP0104258A3/hu unknown
- 1999-10-29 AT AT99951034T patent/ATE380020T1/de active
- 1999-10-29 EP EP99951034A patent/EP1148872B1/en not_active Expired - Lifetime
- 1999-10-29 CZ CZ20011727A patent/CZ302562B6/cs not_active IP Right Cessation
- 1999-10-29 SK SK809-2001A patent/SK8092001A3/sk unknown
- 1999-10-29 IL IL14375999A patent/IL143759A0/xx unknown
- 1999-10-29 YU YU35501A patent/YU35501A/sh unknown
- 1999-10-29 JP JP2000587746A patent/JP2002532409A/ja active Pending
- 1999-10-29 US US09/600,436 patent/US6680341B1/en not_active Expired - Fee Related
- 1999-10-29 TR TR2001/01235T patent/TR200101235T2/xx unknown
- 1999-10-29 PL PL99347686A patent/PL347686A1/xx unknown
-
2001
- 2001-05-07 HR HR20010325A patent/HRP20010325A2/hr not_active Application Discontinuation
- 2001-05-10 ZA ZA200103802A patent/ZA200103802B/en unknown
- 2001-05-15 IS IS5939A patent/IS5939A/is unknown
- 2001-06-04 BG BG105559A patent/BG105559A/bg unknown
- 2001-06-14 IL IL143759A patent/IL143759A/en not_active IP Right Cessation
-
2003
- 2003-09-04 US US10/655,263 patent/US20040072894A1/en not_active Abandoned
-
2008
- 2008-07-11 US US12/172,143 patent/US20090264497A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG105559A (bg) | Стабилен фармацевтичен състав включващ hmg - coa редуктазен инхибитор | |
AU3006992A (en) | Stabilized Pharmeceutical Compositions of HMG-CoA Reductase Inhibitors | |
IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
CA2324283A1 (en) | Pharmaceutical composition containing a statin and aspirin | |
EP0433842A3 (en) | 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them | |
WO2000048626A3 (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease | |
IL141785A0 (en) | A pharmaceutical composition containing an ap2 inhibitor | |
PL362764A1 (en) | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same | |
IL154977A0 (en) | Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent | |
WO1996009827A3 (en) | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor | |
CA2238553A1 (en) | Cholesterol-lowering composition | |
GEP20053548B (en) | Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents | |
PT1200385E (pt) | Cristais do sal de sodio de pravastatina | |
DK0679393T3 (da) | Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol | |
WO2002089788A3 (en) | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor | |
MY118381A (en) | Statin-carboxyalkylether combinations | |
AU1166101A (en) | Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative | |
ATE418979T2 (de) | Stabilisiertes arzneimittel und arzneizubereitung | |
CA2375378A1 (en) | Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines | |
BG106918A (bg) | Метод за получаване на натриеви соли на статините | |
AU2116201A (en) | A therapeutic mixture of hmg-coa reductase inhibitors | |
HUP0301728A2 (hu) | HMG-CoA reduktázt gátló gyógyászati készítmények és alkalmazásuk | |
TH52206A (th) | สารที่รวมเข้าด้วยกันของ สแททิน-คาร์บอกซิแอลคิลอีเธอร์ | |
AU2001289428A1 (en) | Oral pharmaceutical composition containing a combination of fenofibrate and a hmg-coa reductase inhibitor | |
ATE288751T1 (de) | Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker |